Biotechnology

I Peace's cell manufacturing facility "Peace Engine Kyoto" receives third-party certification as US cGMP compliant: the facility now meets the standard for both the US and Japanese markets

PALO ALTO, Calif., May 25, 2021 /PRNewswire/ -- I Peace, Inc. (CEO: Koji Tanabe ), aPalo Alto-based biotech start-up focusing on Nobel Prize-winning technology "induced pluripotent stem cells (iPSCs)" received a third-party certification as US FDA cGMP compliant for its manufacturing facility "Pea...

2021-05-26 03:00 1211

Procyrion Announces Successful First-in-Human Cases in Cardiorenal Syndrome (CRS) Patients with Aortix™ Percutaneous Mechanical Circulatory Support Device

Pilot CRS Study to Evaluate Performance of Novel Aortix device in Australia and the U.S. HOUSTON, May 25, 2021 /PRNewswire/ -- Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today successful treatment of the fir...

2021-05-25 19:02 911

Singapore-based HeMo Bioengineering Receives China's NMPA Approval for flagship Afentta(TM) Aspiration Catheter

SINGAPORE, May 24, 2021 /PRNewswire/ -- HeMo Bioengineering Ltd ("HeMo"), a Singapore-based medical device company with a focus on treating stroke patients, is pleased to announce that its Afentta™ intracranial thrombectomy aspiration catheter – a product developed byHeMo's branch in China – has ...

2021-05-24 20:01 1488

A 'Game Changer' COVID-19 drug from Korea was introduced in a world class academic journal

SEOUL South Korea, May 23, 2021 /PRNewswire/ -- Hyundai Bioscience (KOSDAQ 048410) announced on the 24th that CNPharm, its major shareholding bio tech company, published an article containing the research results of CP-COV03, a Niclosamide-based oral treatment for COVID-19 based on its proprietar...

2021-05-24 08:16 1490

Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine

CAMBRIDGE, Mass. and INCHEON, South Korea, May 22, 2021 /PRNewswire/ -- Moderna (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Samsung Biologics (KRX: 207940.KS), a leading global CDMO providing a fully integrated end-to-end contract develop...

2021-05-23 00:00 8652

Kintor Announced (1) FDA Has Greenlighted Proxalutamide's Phase III Study for Hospitalized Male and Female COVID-19 Patients to Be Conducted; and (2) Inclusion of Female Outpatients in Proxalutamide's Phase III Study for Mild to Moderate COVID-19

SUZHOU, China, May 19, 2021 /PRNewswire/ -- On May 18, Kintor Pharmaceutical Limited (HKEX.9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the U.S. Food and Drug Administration (FDA) has greenlighted proxalutamide's ph...

2021-05-20 09:47 8589

Duality Biologics Completed $90 Million Series B Financing

PRINCETON, N.J. and SHANGHAI and SUZHOU, China, May 19, 2021 /PRNewswire/ -- Duality Biologics (DualityBio or Company), an innovative biotech company, announced the completion of$90 million series B financing today. This round of financing was led by Lilly Asia Ventures (LAV) and jointly invested...

2021-05-20 08:00 1430

Gracell Biotechnologies to Present Updated Results of GC012F FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma at ASCO 2021 and EHA 2021

SUZHOU, China and PALO ALTO, Calif., May 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, is presenting updated ...

2021-05-20 05:15 8350

ThinkCyte Secures $26 million in Series B Financing

TOKYO, May 19, 2021 /PRNewswire/ -- ThinkCyte, Inc., a company focusing on the development of novel cell therapy, drug discovery and diagnostic platforms, announced today the completion of a $26 million (JPY 2.85 billion) Series B financing, led by SPARX Group with participation from Sysmex Corpo...

2021-05-19 22:00 1914

Island Pharmaceuticals granted key patent for ISLA-101 in the United States

* Island's lead asset, ISLA-101 granted key patent from United Stated Patent & Trademark Office * Patent underpins Island's drug repurposing strategy to rapidly and efficiently develop antiviral therapies with a key focus being mosquito borne viral diseases, such as dengue fever. * Around 3...

2021-05-19 19:30 1379

GeneQuantum Raises Hundreds of Millions RMB in Series C Funding

SUZHOU, China, May 18, 2021 /PRNewswire/ -- GeneQuantum Healthcare (Suzhou) Co., Ltd. (hereinafter "GeneQuantum") announced the completion of Series C fund raising of several hundreds of millions RMB. This series of fund raising is led by China Life Private Equity Investment, jointly by PICC Capi...

2021-05-19 10:30 1506

Firmenich Enters Strategic Partnership with Essential Labs, LLC, a Leading B2B E-Commerce Supplier of Fragrance Solutions

GENEVA, May 18, 2021 /PRNewswire/ -- Firmenich, the world's largest privately-owned fragrance and taste company, has entered into a strategic partnership with Essential Labs, LLC, a leading B2B supplier of fragrance solutions supporting entrepreneurial, independent businesses in the premium home...

2021-05-18 23:00 1867

Arctic Vision announces exclusive licensing agreement with ActualEyes

To develop and commercialize cell therapy to potentially replace corneal endothelial keratoplasty inGreater China and South Korea * Arctic Vision to partner with ActualEyes to introduce novel approach of using cultured corneal endothelial cells to treat corneal endothelial dysfunction and pote...

2021-05-14 20:00 2769

Luye Life Sciences Unveils Cutting-edge Advances in Gene and Cell Therapy at ASGCT 2021

BOSTON, May 13, 2021 /PRNewswire/ -- The Boston R&D Center and GeneLeap Biotech, two subsidiaries of Luye Life Sciences Group, took part in the 24th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, presenting the progress of four of the company's latest preclinical developments in ...

2021-05-14 11:58 1806

An oral antiviral drug from Korea may be a problem solver for COVID-19

SEOUL, South Korea, May 13, 2021 /PRNewswire/ -- Hyundai Bioscience (KOSDAQ 048410) announced that Dr.Jin-Ho Choi, a Chief Scientist of its major shareholding bio tech company CNPharm and Chair Professor at Dankook University, presented the study titled 'COVID-19 Game Changer Drug – a novel orga...

2021-05-13 16:37 1503

Pregene and Dr. Reddy's Announce License Agreement for Anti-BCMA CAR-T PRG1801 in India

BEIJING, May 13, 2021 /PRNewswire/ -- Beijing Time May 10, 2021 — Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) and Shenzhen Pregene Biopharma Co., Ltd. today announced an agreement whereby Dr Reddy's will acquire an exclusive license in the Republic ofInd...

2021-05-13 15:21 1413

Gracell Biotechnologies Appoints Seasoned Gene & Cell Therapy Executive Dr. Jenny (Yajin) Ni as Chief Technology Officer

SUZHOU and SHANGHAI, China, May 10, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the appoin...

2021-05-11 04:01 2192

PharmAbcine Announces Encouraging Non-clinical Data of PMC-403 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

DAEJEON, South Korea, May 10, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company presented an e-poster featuring non-clinical data of PMC-403 at the Association for Resea...

2021-05-10 20:00 1244

Bionomics BNC210 Expansion into Social Anxiety Disorder

* Rapid oral absorption of BNC210 novel tablet formulation ideally suited for acute treatment of anxiety in patients with Social Anxiety Disorder * BNC210 Phase 2b PTSD trial on target for start in mid-2021 with U.S. CRO Premier Research selected and clinical site identification underway * P...

2021-05-10 18:00 2969

Alebund Pharmaceuticals Raises $60 million in Series B Financing Round to Accelerate Its Development of Innovative Drugs and Total Solutions for the Treatment of Renal Diseases

SHANGHAI, May 9, 2021 /PRNewswire/ -- Alebund Pharmaceuticals ("Alebund" or the "Company"), a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions, today announced that it has raised$60 million in its Series B fi...

2021-05-10 08:13 1477
1 ... 85868788899091 ... 112